Profile data is unavailable for this security.
About the company
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company is developing nucleic acid therapies targeting ribonucleic acid (RNA) to address both genetic and non-genetic neurological disorders. Its lead program is a non-opioid pain analgesic directed against the genetically validated target SCN9A. It is engaged in discovery efforts across a range of indications and therapeutic targets, such as pain using non-opioid analgesics, as well as rare neurological genetic disorders, including Huntington's disease, Angelman Syndrome, Batten disease, spinocerebellar ataxia, and sporadic amyotrophic lateral sclerosis (ALS). The Company focuses on pursuing out-licensing opportunities for its clinical asset, cavrotolimod, as well as for its preclinical candidates, including the SCN9A program for neuropathic pain.
- Revenue in USD (TTM)23.79m
- Net income in USD3.07m
- Incorporated2017
- Employees7.00
- LocationExicure Inc2430 N. HALSTED ST.CHICAGO 60614United StatesUSA
- Phone+1 (847) 673-1700
- Fax+1 (847) 556-6411
- Websitehttps://www.exicuretx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Artelo Biosciences Inc | 0.00 | -9.29m | 4.20m | 6.00 | -- | 0.3528 | -- | -- | -3.12 | -3.12 | 0.00 | 3.69 | 0.00 | -- | -- | 0.00 | -55.51 | -- | -59.59 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.87 | -- | -- | -- |
| SYBLEU Inc | 11.70k | -307.88k | 4.30m | -- | -- | -- | -- | 367.87 | -0.0293 | -0.0293 | 0.0011 | -0.0367 | 0.0641 | -- | -- | -- | -168.63 | -- | -- | -- | -- | -- | -2,631.45 | -- | -- | -8.48 | 4.96 | -- | 0.00 | -- | 26.51 | -- | -- | -- |
| Bio Path Holdings Inc | 0.00 | -16.08m | 4.32m | 10.00 | -- | 3.87 | -- | -- | -35.76 | -35.76 | 0.00 | 0.7136 | 0.00 | -- | -- | 0.00 | -167.56 | -70.80 | -206.12 | -76.87 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.94 | -- | -- | -- |
| China Pharma Holdings Inc | 7.01m | -3.08m | 4.34m | 231.00 | -- | 0.4171 | -- | 0.6184 | -1.06 | -1.06 | 2.07 | 0.7016 | 0.4094 | 2.18 | 15.14 | 30,351.95 | -17.98 | -29.66 | -41.91 | -55.25 | -4.01 | 6.47 | -43.91 | -73.09 | 0.332 | -8.42 | 0.3121 | -- | -13.48 | -10.68 | 22.50 | -- | -25.78 | -- |
| Mosaic Immunoengineering Inc | 0.00 | -1.01m | 4.35m | 3.00 | -- | -- | -- | -- | -0.1397 | -0.1397 | 0.00 | -0.8107 | 0.00 | -- | -- | 0.00 | -457.45 | -- | -- | -- | -- | -- | -- | -- | -- | -35.84 | -- | -- | -- | -- | 57.65 | -- | -- | -- |
| Neximmune Inc | 0.00 | -32.34m | 4.36m | 6.00 | -- | 0.9661 | -- | -- | -30.86 | -30.86 | 0.00 | 3.29 | 0.00 | -- | -- | 0.00 | -125.24 | -115.07 | -178.52 | -165.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.25 | -- | -44.65 | -- |
| GT Biopharma Inc | 0.00 | -7.60m | 4.38m | 2.00 | -- | 0.5855 | -- | -- | -5.57 | -5.57 | 0.00 | 5.41 | 0.00 | -- | -- | 0.00 | -49.26 | -205.36 | -78.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 63.62 | -- | -- | -- |
| Exicure Inc | 23.79m | 3.07m | 4.41m | 7.00 | 0.399 | 0.4545 | 1.07 | 0.1854 | 1.28 | 1.28 | 3.86 | 1.12 | 0.8729 | -- | -- | 1,830,000.00 | 11.25 | -41.75 | 18.34 | -55.57 | -- | -- | 12.88 | -302.07 | -- | -- | 0.00 | -- | 6,068.12 | 24.29 | 95.97 | -- | -59.57 | -- |
| Marijuana Company Of America Inc | 1.50m | -13.01m | 4.42m | 7.00 | -- | -- | -- | 2.95 | -0.0071 | -0.0071 | 0.0003 | -0.0036 | 0.3137 | 5.61 | 7.64 | 214,085.70 | -272.25 | -837.07 | -- | -- | 28.37 | 39.75 | -867.96 | -3,809.92 | 0.031 | -0.6498 | -- | -- | 267.09 | 159.65 | 16.09 | -- | -- | -- |
| Tharimmune Inc | 0.00 | -9.32m | 4.42m | 2.00 | -- | 0.4821 | -- | -- | -13.09 | -13.09 | 0.00 | 0.7778 | 0.00 | -- | -- | 0.00 | -105.69 | -- | -127.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.98 | -- | -- | -- |
| Marizyme Inc | 590.91k | -79.15m | 4.43m | 13.00 | -- | -- | -- | 7.50 | -1.83 | -1.83 | 0.0139 | -0.4704 | 0.0117 | 0.9575 | 12.13 | 45,454.62 | -157.28 | -29.47 | -314.26 | -30.42 | 71.63 | 67.78 | -13,393.85 | -8,518.47 | 0.025 | -0.5887 | -- | -- | 11.04 | 18.20 | -247.03 | -- | -- | -- |
| Gold River Productions Inc. | -100.00bn | -100.00bn | 4.45m | 1.00k | -- | 6.86 | -- | -- | -- | -- | -- | 0.0005 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -100.11 | -- | -- | -- |
| Manuka Inc | 671.00k | -1.14m | 4.48m | 4.00 | -- | -- | -- | 6.68 | -0.0128 | -0.0128 | 0.0066 | -0.0124 | 2.41 | 0.9412 | 37.28 | 167,750.00 | -410.43 | -463.75 | -- | -- | 88.08 | -- | -170.04 | -732.15 | 0.0194 | -- | -- | -- | -- | -- | -854.23 | -- | -- | -- |
| Petros Pharmaceuticals Inc | 5.82m | -13.81m | 4.52m | 21.00 | -- | 0.1628 | -- | 0.7759 | -6.35 | -6.35 | 2.74 | 4.17 | 0.1759 | 0.9524 | 2.69 | 277,256.70 | -24.66 | -32.43 | -33.75 | -68.05 | 71.98 | 62.04 | -140.20 | -201.70 | 1.74 | -- | 0.391 | -- | -2.83 | -16.15 | 31.06 | -- | -- | -- |
| Portage Biotech Inc | 0.00 | -144.90m | 4.55m | 7.00 | -- | 0.1422 | -- | -- | -7.96 | -7.96 | 0.00 | 1.62 | 0.00 | -- | -- | 0.00 | -111.60 | -19.70 | -113.27 | -26.48 | -- | -- | -- | -- | -- | -- | 0.0087 | -- | -- | -- | -520.10 | -- | -- | -- |
| Oragenics Inc | 37.65k | -20.66m | 4.57m | 5.00 | -- | 1.99 | -- | 121.39 | -8.69 | -8.69 | 0.0167 | 1.03 | 0.0038 | -- | -- | 7,530.00 | -209.44 | -97.60 | -252.98 | -106.24 | -- | -- | -54,862.55 | -36,169.75 | -- | -- | 0.0898 | -- | -71.37 | -- | -44.56 | -- | 51.64 | -- |
Data as of May 02 2024. Currency figures normalised to Exicure Inc's reporting currency: US Dollar USD
3.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Millennium Management LLCas of 31 Dec 2023 | 57.82k | 0.67% |
| Geode Capital Management LLCas of 31 Dec 2023 | 53.00k | 0.61% |
| Northwestern University (Investment Management)as of 31 Mar 2024 | 52.15k | 0.60% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 49.50k | 0.57% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 40.09k | 0.46% |
| Virtu Americas LLCas of 31 Dec 2023 | 18.67k | 0.22% |
| Two Sigma Securities LLCas of 31 Dec 2023 | 16.73k | 0.19% |
| Tower Research Capital LLCas of 31 Dec 2023 | 6.97k | 0.08% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 5.13k | 0.06% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 2.27k | 0.03% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
